Trial Profile
A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 09 Jan 2016 New trial record